Jump to Navigation

ELLSA™ Exosome Assay

To support our therapeutic advances to eliminate the presence of deleterious exosomes from circulation, our researchers needed to create a diagnostic tool that would provide greater detection sensitivity than other products available in the marketplace.  The result was ELLSA™, an enzyme-linked lectin-specific assay that has demonstrated the ability to identify and quantify the presence of exosomes underlying human immunodeficiency virus (HIV), tuberculosis (TB), and all forms of cancer tested to date.  As our focus is directed towards advancing the pipeline of Aethlon ADAPT™ system therapies, we plan to license or sell this technology to an organization already established in the research diagnostics field.


Site 'Subpage' Navigation:

Product Pipeline

Back to Top